Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825510 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
A Phase 2 study, sponsored by Crozer-Keystone Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03825510 is a Phase 2 study that has completed, run by Crozer-Keystone Health System. The registered enrollment target is 3 participants.
The verdict
NCT03825510, a Phase 2 study, has completed, sponsored by Crozer-Keystone Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine efficacy, safety of Stereotactic Body Radiotherapy (SBRT) in combination with immunotherapy in participants with metastatic non-small cell lung cancer (NSCLC) who are eligible for an immunotherapy agent.
Interventions
- RADIATION Stereotactic Body Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2022-03-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03825510
The ClinicalTrials.gov registry entry for NCT03825510 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crozer-Keystone Health System, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Body Radiotherapy is the first listed.
NCT03825510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03825510 about?
NCT03825510 is a clinical study titled "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect". The purpose of this study is to determine efficacy, safety of Stereotactic Body Radiotherapy (SBRT) in combination with immunotherapy in participants with metastatic non-small cell lung cancer (NSCLC) who are eligible for an immunotherapy agent.
What is the current status of trial NCT03825510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-04-28. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT03825510?
The interventions under investigation include: Stereotactic Body Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03825510?
This trial is sponsored by Crozer-Keystone Health System, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.